- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05970315
Prioriteiten afgestemd Afschaffing van voorschrift voor personen met dementie en hun verzorger
The purpose of this study is to compare patient priorities care (PPC) and usual care (UC) patients to identify differences in post-encounter medication changes, treatment burden (TBQ), and shared decision making in Older Patient Assessment of Chronic Illness Care (OPACIC), to understand PPC participant's sense-making and communication approaches related to deprescribing decisions in relation to the identified health priorities and to identify and categorize adverse drug withdrawal events (ADWEs)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- The University of Texas Health Science Center at Houston
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Dementia listed as an active problem in the medical record, including Alzheimer's disease, vascular dementia, frontotemporal dementia, Parkinson's dementia, Lewy body disease.
- The functional assessment staging tool (FAST) score of 5 or lower (This will be established by the patient's clinician).
- 2 or more additional chronic conditions
- Takes 5 or more regular medications and
- A caregiver present during visits. Caregivers may include family members or unrelated caregivers and will be identified through chart review and confirmed by clinician, patient, and surrogate decision maker if necessary. Identified caregivers must be involved in decisions and care of People living with dementia (PLWD) and routinely attend clinic visits with patient
Exclusion Criteria:
- FAST score of 6 or more (This will be established by the patient's clinician).
- Significant hearing, vision, or advanced cognitive impairment that limits ability to participate in PPC encounters,
- Caregiver is unwilling or able to participate in visits, or
- Deemed ineligible by their Primary care physician (PCP)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Gebruikelijke zorg
|
Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden. |
|
Experimenteel: PPC
|
Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total Number of Medication Changes
Tijdsspanne: Baseline, 3 month
|
Total Number of medication changes that happened between baseline and three month follow up among Dementia Participants. |
Baseline, 3 month
|
|
Type of Medication Changes
Tijdsspanne: Baseline, 3 month
|
Medication changes corresponding to the type of changes among Dementia Participants: added or increased, discontinued or decreased, avoided. |
Baseline, 3 month
|
|
Number of Participants by Change in Patient Report Treatment Burden as Assessed by the Treatment Burden Questionnaire (TBQ)
Tijdsspanne: Baseline, 3 month
|
The questionnaire consists of 15 items, each scored on a scale from 0 (not a problem) to 10 (a very big problem), yielding a total score range of 0 to 150, with higher scores indicating greater treatment burden. TBQ total scores were assessed at baseline and at 3 months. Change in treatment burden was calculated by subtracting the baseline total TBQ score from the 3-month TBQ score (3 month minus baseline). Participants were categorized based on change in score as follows:
|
Baseline, 3 month
|
|
Number of Participants by Likelihood of Adverse Drug Reactions (ADRs) as Assessed by the Naranjo Scale
Tijdsspanne: 3 months
|
Naranjo scale is a questionnaire used to assess the likelihood that an adverse event is related to a drug. Total scores range from -4 to +13. Adverse drug reactions were categorized based on total score as follows:
|
3 months
|
|
Number of Participants by Adverse Drug Withdrawal Events (ADWEs) as Assessed by the Naranjo Scale
Tijdsspanne: 3 months
|
The Naranjo Scale assesses the likelihood that an adverse event is related to a drug withdrawal. Total scores range from -4 to +13. Adverse drug withdrawal events (ADWEs) were categorized as follows:
|
3 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score
Tijdsspanne: Baseline, 3 months
|
The Older Patient Assessment of Chronic Illness Care (OPACIC) score ranges from 10 to 50, with higher scores indicating better perceived chronic disease care. The change in score is reported as [(OPACIC score at 3 months) - (OPACIC score at baseline)]--a positive value indicates improvement in perceived chronic disease care over time. |
Baseline, 3 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Aanand D Naik, MD, The University of Texas Health Science Center, Houston
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HSC-SPH-22-0639
- 5R24AG064025-05 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .